The term "FER1" refers to different proteins depending on the organism:
Chlamydomonas FER1: A ferritin subunit involved in iron storage and homeostasis. It forms part of a 25 kDa monomeric protein complex, distinct from the trimeric FER2 ferritin ( ).
Human/mouse FER (FER1): A proto-oncogene-encoded tyrosine kinase (UniProt: P16591) regulating cell adhesion, migration, and immune responses. Commercial FER1 antibodies (e.g., Proteintech 25287-1-AP) target this protein ( ).
Toxoplasma FER1: A ferlin-family protein (159 kDa) critical for microneme organelle trafficking and exocytosis in Toxoplasma gondii ( ).
Toxoplasma FER1: Polyclonal antiserum against the C2DE domain detects full-length FER1 (159 kDa) and fragments (120 kDa, 30 kDa) in Western blots ( ).
Anti-FER1 antibodies immunopurify ferritin1 complexes, revealing a 70:1 abundance ratio of FER1:FER2 subunits under iron-replete conditions ( ).
Subcellular localization studies demonstrate FER1’s role in cytoplasmic iron sequestration ( ).
Proteintech’s FER1 antibody detects FER tyrosine kinase in:
Overexpression of FER correlates with tumor progression and chemoresistance in colorectal cancer models ( ).
Choose antibodies based on three factors:
Application specificity: Western blot (WB) requires antibodies recognizing denatured epitopes (e.g., Proteintech 67671-1-PBS targets FER in WB/IF/ICC ), while immunofluorescence (IF) needs antibodies against native conformations.
Epitope region: For functional studies, select antibodies targeting domains critical for FER1 activity (e.g., C2DE domain antibodies in Toxoplasma FER1 studies ).
Validation rigor: Prioritize antibodies with knockout-validated specificity (e.g., fer-1 mutant controls in C. elegans ).
| Antibody Performance Across Studies |
|---|
| Application |
| ------------------ |
| WB/IF/ICC |
| ImmunoEM |
| Subcellular IFA |
Western blot: Compare observed (95 kDa for human FER ) vs. predicted molecular weight.
Knockout controls: Use FER1 deletion mutants (e.g., Chlamydomonas FER1/2 iron-response studies ).
Orthogonal localization: Confirm subcellular patterns with independent markers (e.g., FER1 apical-nuclear localization vs. MIC2 in Toxoplasma ).
Test multiple antibodies against distinct domains (e.g., C2DE vs. DysfNC domains ).
Pre-absorb antibodies with recombinant FER1 protein (see C. elegans immunoelectron microscopy protocols ).
Validate using conditional depletion models (e.g., Shield-1-stabilized dominant-negative FER1 mutants ).
Contradictions arise from:
Environmental stimuli: FER1 relocalizes from apical-nuclear regions (intracellular parasites) to cytoplasm (extracellular) in Toxoplasma .
Fixation artifacts: Use live-cell imaging tags (e.g., DD-Myc-FER1∆TM ) to bypass antibody-dependent methods.
Species-specific isoforms: Compare Chlamydomonas FER1 (chloroplastic ) vs. human FER (cytosolic ).
| Localization Discrepancies |
|---|
| System |
| --------------------- |
| Toxoplasma |
| Toxoplasma |
| C. elegans sperm |
Functional assays: Combine propranolol-induced Ca²⁺-independent secretion with FER1 antibody-based microneme tracking .
Genetic perturbations: Use conditional FER1 mutants (e.g., auxin-inducible degron) alongside quantitative IF .
Dynamic imaging: Employ time-lapse microscopy with FER1/MIC2 dual labeling to monitor trafficking .
Epitope conservation analysis: Align sequences across species (e.g., human FER vs. Chlamydomonas FER1 ).
Empirical validation: Test antibody reactivity in phylogenetically distant systems (e.g., C. elegans vs. mammalian cells ).
Domain-specific blocking: Pre-incubate antibodies with recombinant proteins from non-target species.
Subunit-specific antibodies: Use antibodies targeting non-conserved regions (e.g., Chlamydomonas FER1 vs. FER2 ).
Quantitative proteomics: Combine immunoprecipitation with mass spectrometry to distinguish paralog contributions.
Gene silencing: Perform RNAi knockdown of individual paralogs followed by antibody validation .